European shares were unchanged on Friday, as losses in heavyweight healthcare shares were countered by an advance in oil and ...

The Sensex dropped 502 points on Friday to close at 81,758, while the Nifty slipped 143 points to end below the 25,000 mark ...

For new and old investors, taking full advantage of the stock market and investing ... its share price will decline as well. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, ...

GlaxoSmithKline Pharmaceuticals, with its shares currently priced at Rs 3,292.30, remains a key stock to watch, particularly for those invested in or tracking the NIFTY MIDCAP 150 index.

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval of Nucala for chronic obstructive pulmonary disease (COPD) and a ...

Our Take on GILD’s Performance Gilead’s first-quarter results were disappointing as a decline in oncology drugs affected revenue growth.

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company announced a $2.5 billion share buyback plan.

Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.

In other recent news, GlaxoSmithKline PLC (GSK) has reported a substantial performance in its third-quarter earnings call, with a 9% sales growth and a 19% profit growth year-to-date. The company's ...

In other recent news, GlaxoSmithKline PLC (GSK) has reported a substantial performance in its third-quarter earnings call, with a 9% sales growth and a 19% profit growth year-to-date.